Resveratrol: A promising agent in targeting senescent cancer-associated fibroblasts to inhibit pancreatic cancer progression.

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis and limited therapeutic options. The tumor microenvironment (TME), including cancer-associated fibroblasts (CAFs), plays a pivotal role in tumor progression and therapy resistance. Senescent CAFs, which exhibit a senescence-associated secretory phenotype (SASP), further exacerbate cancer growth through inflammatory cytokine secretion. This editorial highlights a study by Jiang , which investigates the potential of resveratrol, a natural polyphenolic compound, in targeting senescent CAFs to inhibit pancreatic cancer progression. The study demonstrates that resveratrol reduces senescent CAFs and downregulates SASP factors, thereby disrupting the pro-tumorigenic activities of these cells. Resveratrol's ability to modulate the TME, induce apoptosis in pancreatic cancer cells, and inhibit metastasis underscores its potential as an adjunctive therapy. This research offers promising insights into novel strategies for improving therapeutic outcomes in pancreatic cancer by targeting the TME and senescent CAFs.